GL6 (O-13287)

$5,000.00

GL6-based LNPs exhibit significant liver editing capability from 5% to 61% in the NHP model and resulted in an 89% reduction in ANGPTL3 protein in the blood for 6 months after administration.

For Research Use Only.

Sold under the Hatch-Waxman exemption (safe harbor exemption)

GL6 (O-13287)

CAS# N/A

GL6-based LNPs exhibit significant liver editing capability from 5% to 61% in the NHP model and resulted in an 89% reduction in ANGPTL3 protein in the blood for 6 months after administration.

For Research Use Only.

Sold under the Hatch-Waxman exemption (safe harbor exemption)

GL6 (O-13287)

CAS# N/A